BioCentury
ARTICLE | Clinical News

Delzicol mesalamine regulatory update

February 18, 2013 8:00 AM UTC

FDA approved an NDA from Warner Chilcott said for 400 mg Delzicol mesalamine delayed-release capsules to treat mildly to moderately active ulcerative colitis (UC) and for maintenance remission of UC. ...